| Metagenomics Market Forecast 2026–2034: Trends & Insights |
|
| According to a newly published market research report by 24LifeSciences, global metagenomics market was valued at USD 229 million in 2024 and is projected to reach USD 447 million by 2031, growing at a compound annual growth rate (CAGR) of 10.3% duri |
| read more |
|
|
| What Is Driving the Biocatalysis and Biocatalysts Market Toward USD 4.86B by 2032 at a 9.1% CAGR? |
|
| Global biocatalysis and biocatalysts market size was valued at USD 2.17 billion in 2024. The market is projected to grow from USD 2.42 billion in 2025 to USD 4.86 billion by 2032, exhibiting a CAGR of 9.1% during the forecast period.Biocatalysis invo |
| read more |
|
|
| Inferior Vena Cava (IVC) Filters Market Forecast 2026–2034: Trends & Insights |
|
| According to a newly published market research report by 24LifeSciences, global inferior vena cava (IVC) filters market was valued at USD 696 million in 2024 and is projected to reach USD 1,146 million by 2031, growing at a compound annual growth rat |
| read more |
|
|
| Shoulder Arthroscopy Visualization Systems Market Size, Share & Revenue Outlook 2032 |
|
| According to a newly published market research report by 24LifeSciences, the global shoulder arthroscopy visualization systems market was valued at USD 1.4 billion in 2024 and is projected to reach USD 2.1 billion by 2032, growing at a compound annua |
| read more |
|
|
| Endobronchial Blocker Market Forecast 2026–2034: Trends & Insights |
|
| According to a newly published market research report by 24LifeSciences, global Endobronchial Blocker market was valued at USD 6.5 million in 2024 and is projected to reach USD 8.5 million by 2031, growing at a compound annual growth rate (CAGR) of 3 |
| read more |
|
|
| Dry Eye Disease Market 4.9% CAGR: Top Companies in 2026 |
|
| According to a newly published market research report by 24LifeSciences, the global dry eye disease market was valued at USD 5.37 billion in 2024 and is projected to reach USD 7.48 billion by 2031, growing at a compound annual growth rate (CAGR) of 4 |
| read more |
|
|
